The South African Nuclear Energy Corporation NECSA and Sibanye-Stillwater have signed a collaboration agreement to advance the development of nuclear medicine technologies for cancer treatment, expanding South Africas role in radiopharmaceutical innovation.
The partnership will focus on the development of radioactive palladium-103 Pd-103: a medical isotope used in brachytherapy procedures for the treatment of prostate cancer and other forms of the disease.
According to the organisations, the project will investigate the use of rhodium supplied by Sibanye-Stillwater as feedstock for the production of Pd-103 at NECSAs nuclear facilities.
